EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Outcome of magnetic resonance guided stereotactic body radiotherapy for hepatocellular carcinoma - an R-IDEAL stage IIb trial

Marcel Büttner, Laura Uder, Marcel Nachbar, Monica Lo Russo, David Mönnich, Moritz Schneider, Jessica Boldt, Sarah Kübler, Sabrina Baumeister, Michael Bitzer, Silvio Nadalin, Rüdiger Hoffmann und 4 weitere

Clinical and Translational Radiation Oncology · 2027-01 · 62 · 101346

DOI: 10.1016/j.ctro.2026.101346 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical and Translational Radiation Oncology, 2027-01. Verfasst von Marcel Büttner und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, University Hospital and Medical Faculty, Eberhard Karls University Tübingen, Tübingen, Germany. Die Arbeit nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Deutsche Forschungsgemeinschaft.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Stereotactic body radiation therapy (SBRT) for hepatocellular carcinoma (HCC) is gaining increasing importance as a non-invasive, ablative treatment. However, there are still limited data on online magnetic resonance imaging-guided SBRT (MRgSBRT) for HCCs using MR linear accelerators. The aim of this study was to evaluate the feasibility, safety, and oncological outcomes of online adaptive MRgSBRT in patients with HCC. Material and methods: All patients who underwent liver MR-guided SBRT for HCC using fraction doses of at least 5 Gy between August 2019 and September 2024 were included. All patients were treated on a 1.5 T magnetic resonance (MR-)-Linac with MR imaging for online adaptation and motion monitoring at each fraction. Treatment-related parameters, local control (LC), overall survival (OS) and progression-free survival (PFS) are reported.

Results

A total of 45 patients with 51 lesions were treated with online adaptive MRgSBRT. Median age was 72 (interquartile range, IQR 67 to 78) years. Liver-directed treatments prior to the SBRT had been applied in 53% of patients. A median of 35 (IQR of 35 to 40) Gray (Gy) was applied with a median of 5 fractions. Median follow-up was 28 months (95% confidence interval, CI: 21-35). LC at 12 and 24 months was 94% (95% CI: 86-100) and 90% (95% CI 79-100). OS after 12 and 24 months were 84% (95% CI: 73-96) and 70% (95% CI: 56-87) and PFS was 54.7% (95% CI: 41-74) and 29% (95% CI: 17%-50%). Of the 14 patients treated for bridging 8 patients (57%) proceeded to receive liver transplantation. No acute adverse events beyond CTCAE grade 2 were documented.

Conclusion

Non-invasive, online adaptive MRgSBRT for HCC in this prospective cohort of patients proved to be well tolerated with excellent local control and is therefore a viable treatment option for patients with HCC.

Schlagwörter

Stichwörter der Autor:innen

Bridging therapy to liver transplantationLocal controlMagnetic resonance linear acceleratorMagnetic resonance-guided radiotherapyOnline adaptive radiotherapyProspective cohort studyReal-time magnetic resonance imagingRespiratory motion managementStereotactic body radiotherapyhepatocellular carcinoma

Autor:innen und Institutionen

  • Department of Radiation Oncology, University Hospital and Medical Faculty, Eberhard Karls University Tübingen, Tübingen, Germany.
  • German Cancer Consortium (DKTK), partner site Tübingen; and German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Section for Biomedical Physics, Department of Radiation Oncology, University Hospital and Medical Faculty, Eberhard Karls University Tübingen, Tübingen, Germany.
  • Department of Internal Medicine I, University Hospital Tübingen, Tübingen, Germany.
  • Department of General, Visceral and Transplant Surgery, University Hospital Tübingen, Tübingen, Germany.
  • Department of Diagnostic and Interventional Radiology, University of Tübingen, Germany.

Förderung

  • Deutsche Forschungsgemeinschaft

Zitieren

APA

Büttner, M., Uder, L., Nachbar, M., Russo, M. L., Mönnich, D., Schneider, M., Boldt, J., Kübler, S., Baumeister, S., Bitzer, M., Nadalin, S., Hoffmann, R., Thorwarth, D., Niyazi, M., Gani, C., & Boeke, S. (2027). Outcome of magnetic resonance guided stereotactic body radiotherapy for hepatocellular carcinoma - an R-IDEAL stage IIb trial. Clinical and Translational Radiation Oncology, 62, 101346. https://doi.org/10.1016/j.ctro.2026.101346

Vancouver

Büttner M, Uder L, Nachbar M, Russo ML, Mönnich D, Schneider M, et al. Outcome of magnetic resonance guided stereotactic body radiotherapy for hepatocellular carcinoma - an R-IDEAL stage IIb trial. Clinical and Translational Radiation Oncology. 2027;62:101346. doi:10.1016/j.ctro.2026.101346

BibTeX
@article{Bttner2027,
  author = {Büttner, Marcel and Uder, Laura and Nachbar, Marcel and Russo, Monica Lo and Mönnich, David and Schneider, Moritz and Boldt, Jessica and Kübler, Sarah and Baumeister, Sabrina and Bitzer, Michael and Nadalin, Silvio and Hoffmann, Rüdiger and Thorwarth, Daniela and Niyazi, Maximilian and Gani, Cihan and Boeke, Simon},
  title = {Outcome of magnetic resonance guided stereotactic body radiotherapy for hepatocellular carcinoma - an R-IDEAL stage IIb trial},
  journal = {Clinical and Translational Radiation Oncology},
  year = {2027},
  volume = {62},
  pages = {101346},
  doi = {10.1016/j.ctro.2026.101346}
}
Kostenlos starten →